Patents by Inventor Damon Meyer

Damon Meyer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10457976
    Abstract: The invention is based in part on the observation that a CHO cell oxidizing enzyme, particularly QSOX1, can survive a seemingly rigorous antibody purification process to reduce subsequent conjugation efficiency of the antibody to a drug. Whether the oxidizing enzyme survives the purification procedure depends on which purification techniques are employed which can vary from one antibody to another. With knowledge that contamination with a CHO cell oxidizing enzyme is a potential problem for subsequent conjugation, a suitable purification scheme can be devised for any antibody that eliminates or at least reduces CHO oxidizing enzyme(s) to an acceptable level.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: October 29, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Kevin Beam, Damon Meyer, Bradley Hayes, Robert Lyon, John Valliere-Douglass
  • Patent number: 10391181
    Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: August 27, 2019
    Assignee: Seattle Genetics, Inc.
    Inventors: Hui Li, Shan Jiang, Mary Wallace, Damon Meyer
  • Publication number: 20180369408
    Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.
    Type: Application
    Filed: April 30, 2018
    Publication date: December 27, 2018
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Hui Li, Shan Jiang, Mary Wallace, Damon Meyer
  • Patent number: 9987374
    Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: June 5, 2018
    Assignee: Seattle Genetics, Inc.
    Inventors: Hui Li, Shan Jiang, Mary Wallace, Damon Meyer
  • Publication number: 20170232112
    Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine antibody-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine antibody-drug conjugates and process drug-related impurities.
    Type: Application
    Filed: March 9, 2017
    Publication date: August 17, 2017
    Applicant: Seattle Genetics, Inc.
    Inventors: Hui Li, Shan Jiang, Mary Wallace, Damon Meyer
  • Publication number: 20170159099
    Abstract: The invention is based in part on the observation that a CHO cell oxidizing enzyme, particularly QSOX1, can survive a seemingly rigorous antibody purification process to reduce subsequent conjugation efficiency of the antibody to a drug. Whether the oxidizing enzyme survives the purification procedure depends on which purification techniques are employed which can vary from one antibody to another. With knowledge that contamination with a CHO cell oxidizing enzyme is a potential problem for subsequent conjugation, a suitable purification scheme can be devised for any antibody that eliminates or at least reduces CHO oxidizing enzyme(s) to an acceptable level.
    Type: Application
    Filed: November 21, 2014
    Publication date: June 8, 2017
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Kevin Beam, Damon Meyer, Bradley Hayes, Robert Lyon, John Valliere-Douglass
  • Patent number: 9610361
    Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine anti-body-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine anti-body-drug conjugates and process drug-related impurities.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: April 4, 2017
    Assignee: Seattle Genetics, Inc.
    Inventors: Hui Li, Shan Jiang, Mary Wallace, Damon Meyer
  • Patent number: 9522194
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand-drug conjugates were active in vitro and in vivo in inhibiting cell proliferation and are represented by the general structure of Lv-[(LU)0-1-(D)1-4]p wherein L- is Ligand unit; LU is a Linker unit (LU); v is 1; p is an number ranging from about 1 to about 20; and D is a drug moiety having the formula: wherein the moiety —N(R9)Z1 is a phenylalanine bioisostere, wherein Z1 is —CH(R10)Z2 so that the phenylalanine bioisostere has the structure of Formula A: and wherein the substituents R2-R10, X1 and Z2 are as defined.
    Type: Grant
    Filed: September 30, 2014
    Date of Patent: December 20, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O Doronina, Toni Beth Kline, Scott Jeffrey, Peter D Senter, Damon Meyer
  • Patent number: 9453046
    Abstract: Disclosed are methods of purifying mixtures comprising benzoidiazepine antibody-drug conjugates.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: September 27, 2016
    Assignee: Seattle Genetics, Inc.
    Inventors: Damon Meyer, Michael Sun
  • Publication number: 20160045615
    Abstract: Disclosed are formulations, including both liquid and lyophilized formulations, comprising a benzodiazepine anti-body-drug conjugate (ADC) and a cyclodextrin. Also disclosed are methods of purifying mixtures comprising benzodiazepine anti-body-drug conjugates and process drug-related impurities.
    Type: Application
    Filed: March 12, 2014
    Publication date: February 18, 2016
    Applicant: Seattle Genetics, Inc.
    Inventors: Hui Li, Shan Jiang, Mary Wallace, Damon Meyer
  • Publication number: 20160039870
    Abstract: Disclosed are methods of purifying mixtures comprising benzoidiazepine antibody-drug conjugates.
    Type: Application
    Filed: March 12, 2014
    Publication date: February 11, 2016
    Applicant: Seattle Genetics, Inc.
    Inventors: Damon Meyer, Michael Sun
  • Publication number: 20150044238
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand-drug conjugates were active in vitro and in vivo in inhibiting cell proliferation and are represented by the general structure of Lv-[(LU)0-1-(D)1-4]p wherein L- is Ligand unit; LU is a Linker unit (LU); v is 1; p is an number ranging from about 1 to about 20; and D is a drug moiety having the formula: wherein the moiety —N(R9)Z1 is a phenylalanine bioisostere, wherein Z1 is —CH(R10)Z2 so that the phenylalanine bioisostere has the structure of Formula A: and wherein the substituents R2-R10, X1 and Z2 are as defined.
    Type: Application
    Filed: September 30, 2014
    Publication date: February 12, 2015
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Svetlana O Doronina, Toni Beth Kline, Scott Jeffrey, Peter D Senter, Damon Meyer
  • Patent number: 8871720
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: October 28, 2014
    Assignee: Seattle Genetics, Inc.
    Inventors: Svetlana O. Doronina, Toni Beth Kline, Scott Jeffrey, Peter D. Senter, Damon Meyer
  • Publication number: 20090111756
    Abstract: Auristatin peptide analogs of MeVal-Val-Dil-Dap-Phe (MMAF) having a carboxylic acid equivalent at the C-terminal phenylalanine were prepared and attached to ligands through various linkers, including maleimidocaproyl-val-cit-PAB. The resulting ligand drug conjugates were active in vitro and in vivo.
    Type: Application
    Filed: July 7, 2006
    Publication date: April 30, 2009
    Applicant: Seattle Genectics, Inc.
    Inventors: Svetlana O. Doronina, Toni Beth Kline, Scott Jeffrey, Peter D. Senter, Damon Meyer
  • Publication number: 20050225105
    Abstract: A self-propelled four-wheel vehicle (1) for travel on land and/or on rails includes four hubs (9) for mounting of wheels including tires (6) for travel on land, four rail wheels (7) for travel on a railway, and four coupling assemblies, for detachably connecting the rail wheels to, outwardly of, and spaced from, the hubs. A kit for converting the vehicle for travel on rails includes, for each hub (9) of the vehicle, a rail wheel adapter (25, 44) including a flange (26, 45) for fastening to a rail wheel (7) and an axle portion (24, 46) extending transverse to the flange, a vehicle wheel adapter (10, 40) including a flange (15, 41) for fastening to a hub of the land vehicle and an axle portion (21, 42) extending transverse to the flange, and a coupler (12, 13) for coupling the rail wheel adapter to the vehicle wheel adapter.
    Type: Application
    Filed: February 20, 2003
    Publication date: October 13, 2005
    Inventor: Damon Meyer
  • Patent number: D871985
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: January 7, 2020
    Assignee: Ford Global Technologies, LLC
    Inventors: Dong Park, Anthony Meyer, Soohyoung Kim, Damon G. Depeyster, Gordon M. Platto